PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16167284-1	2005	PURPOSE: To compare the safety and efficacy of a new enhanced viscosity ophthalmic formulation of tobramycin, given twice daily (BID), with the existing four times daily (QID) treatment regimen in patients with acute bacterial conjunctivitis.	Tobramycin	98-108	BH3 interacting domain death agonist	Homo sapiens	129-132	
28221457-1	2005	PURPOSE: To compare the safety and efficacy of a new enhanced viscosity ophthalmic formulation of tobramycin, given twice daily (BID), with the existing four times daily (QID) treatment regimen in patients with acute bacterial conjunctivitis.	Tobramycin	98-108	BH3 interacting domain death agonist	Homo sapiens	129-132	
12114362-13	2002	CONCLUSIONS: The administration of tobramycin, 300 mg bid, in a 28-day off/28-day on regimen produced low serum tobramycin concentrations, reducing the potential for systemic toxicity.	Tobramycin	35-45	BH3 interacting domain death agonist	Homo sapiens	54-57	
12114362-13	2002	CONCLUSIONS: The administration of tobramycin, 300 mg bid, in a 28-day off/28-day on regimen produced low serum tobramycin concentrations, reducing the potential for systemic toxicity.	Tobramycin	112-122	BH3 interacting domain death agonist	Homo sapiens	54-57